| Dr Mark Everett Bradford Johnson, MD, MBA | |
|
16620 N 40th St, Ste I-5, Phoenix, AZ 85032-3348 | |
| (602) 482-1300 | |
| (480) 718-7342 |
| Full Name | Dr Mark Everett Bradford Johnson |
|---|---|
| Gender | Male |
| Speciality | Pathology - Anatomic Pathology & Clinical Pathology |
| Location | 16620 N 40th St, Phoenix, Arizona |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1134188956 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207ZP0102X | Pathology - Anatomic Pathology & Clinical Pathology | 24917 (Arizona) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Mark Everett Bradford Johnson, MD, MBA 16620 N 40th St, Ste I-5, Phoenix, AZ 85032-3348 Ph: (602) 482-1300 | Dr Mark Everett Bradford Johnson, MD, MBA 16620 N 40th St, Ste I-5, Phoenix, AZ 85032-3348 Ph: (602) 482-1300 |
News Archive
An investigational treatment for Marfan syndrome is as effective as the standard therapy at slowing enlargement of the aorta, the large artery of the heart that delivers blood to the body, new research shows. The findings indicate a second treatment option for Marfan patients, who are at high risk of sudden death from tears in the aorta.
Scientists have conducted a survey in England to investigate the association between smoking habits and distress during the COVID-19 pandemic.
The proteins that have now been identified shouldn't actually exist. Nevertheless, they build the core of cellular aggregates whose identity has been enigmatic until now. These aggregates are typically associated with hereditary neurodegenerative diseases including variants of frontotemporal dementia (FTD), also known as frontotemporal lobar degeneration (FTLD), and amyotrophic lateral sclerosis (ALS). They are likely to be damaging and might be a target for therapy.
In research at SRI International, scientists evaluating new drug targets against tuberculosis (TB) recently validated the preclinical effectiveness of a target that could rapidly eliminate infections and potentially shorten treatment time. The new drug target is a protein called DNA gyrase B, found in bacteria that cause TB infections.
Scientists at The University of Nottingham are leading the world in exploiting MRI technology to assist in the treatment and diagnosis of Irritable Bowel Syndrome, a condition that causes serious inconvenience and discomfort to sufferers.
› Verified 9 days ago
Dr. Natasha Elizabeth Lewis, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 5777 E Mayo Blvd, Phoenix, AZ 85054 Phone: 480-301-8000 | |
Dr. Nasma Kamil Majeed, MD Pathology Medicare: Medicare Enrolled Practice Location: 1111 E Mcdowell Rd, Phoenix, AZ 85006 Phone: 602-685-5211 Fax: 623-322-4639 | |
David J Glembocki, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 11130 N Tatum Blvd, Suite 100, Phoenix, AZ 85028 Phone: 602-494-1817 Fax: 602-494-7103 | |
Suzan Kavusi, MD Pathology Medicare: Not Enrolled in Medicare Practice Location: 650 E Indian School Rd, Phoenix, AZ 85012 Phone: 602-277-5551 | |
Dr. Maria P Alzona, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 424 S 56th St Ste 120, Phoenix, AZ 85034 Phone: 602-685-5211 Fax: 602-685-5325 | |
Anna Marie Felty-duckworth, M.D. Pathology Medicare: Not Enrolled in Medicare Practice Location: 650 E Indian School Rd, Cs/113, Phoenix, AZ 85012 Phone: 602-277-5551 Fax: 602-222-2669 | |
Renuka Pathi, MD Pathology Medicare: Not Enrolled in Medicare Practice Location: 22216 N 36th St, Phoenix, AZ 85050 Phone: 602-606-7375 |